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Objectives. This study was undertaken to examine whether a
dihydropyridine Ca channel blocker, benidipine, increases car-
diac NO levels, and thus coronary blood flow (CBF) in ischemic
hearts.
Background. Benidipine protects endothelial cells against isch-
emia and reperfusion injury in hearts.
Methods and Results. In open chest dogs, coronary perfusion
pressure (CPP) of the left anterior descending coronary artery
was reduced so that CBF decreased to one-third of the control
CBF, and thereafter CPP was maintained constant (103 6 8 to
42 6 1 mmHg). Both fractional shortening (FS: 6.1 6 1.0%) and
lactate extraction ratio (LER: 241 6 4%) decreased. Ten minutes
after the onset of an intracoronary infusion of benidipine
(100 ng/kg/min), CBF increased from 32 6 1 to 48 6 4 ml/100g/
min during 20 min without changing CPP (42 6 2 mmHg). Both
FS (10.7 6 1.2%) and LER (216 6 4%) also increased. Benidipine
increased cardiac NO levels (11 6 2 to 17 6 3 nmol/ml). The
increases in CBF, FS, LER and cardiac NO levels due to benidip-
ine were blunted by L-NAME. Benidipine increased cyclic GMP
contents of the coronary artery of ischemic myocardium (139 6 13
to 208 6 15 fmol/mg protein), which was blunted by L-NAME.
Conclusion. Thus, we conclude that benidipine mediates coro-
nary vasodilation and improves myocardial ischemia through
NO-cyclic GMP-dependent mechanisms.
(J Am Coll Cardiol 1999;33:242–9)
©1998 by the American College of Cardiology
Calcium (Ca) channel blockers are widely used for the treat-
ment of ischemic heart diseases because of the capability of
effective coronary vasodilation (1,2). Ca channel blockers are
believed to increase coronary blood flow (CBF) due to inhibi-
tion of Ca21 entry into the smooth muscle cells (3). Recently,
benidipine, a dihydropyridine Ca channel blocker, can protect
endothelial cellular function of renal resistance arteries of
hypertensive rats (4), and mesenteric arteries of the circulatory
shock rats (5). Endothelial function is important for the
preservation of the organ function against ischemic or hyper-
tensive stress (6–8), and indeed, benidipine is reported to be
cardioprotective against myocardial ischemia and reperfusion
injury (9). These observations suggest that benidipine may be
protective against endothelial dysfunction during ischemia and
reperfusion in the heart. Since myocardial ischemia deterio-
rates endothelial functions via the activation of platelets and
leukocytes (10,11), benidipine may attenuate the endothelial
functions and increase the production of nitric oxide in the
ischemic hearts.
Therefore, we examined the idea that benidipine increases
CBF via nitric oxide (NO)-dependent mechanisms in the
canine hearts. Since dihydropyridine Ca channel blockers are
reported to inhibit adenosine uptake (12,13), we also tested
whether the effects of benidipine on coronary vasodilation in
the ischemic hearts are attributable to adenosine.
Material and Methods
Instrumentation. Mongrel dogs weighing 14–26 kg were
anesthetized with sodium pentobarbital (30 mg/kg, IV). The
trachea was intubated and the dog was ventilated with room air
mixed with oxygen. The chest was opened through the left fifth
intercostal space, and the heart was suspended in a pericardial
cradle. A proximal portion of the left anterior descending
coronary artery (LAD) was cannulated and perfused with
blood via the left carotid artery through an extracorporeal
bypass tube. Coronary perfusion pressure (CPP) was moni-
tored at the tip of the coronary arterial cannula, and CBF in
the perfused area was measured with an electromagnetic flow
probe attached at the bypass tube.
In 37 dogs (Protocols I–III), a small, short collecting tube
(diam: 1 mm, length: 7 cm) was inserted into a small coronary
vein near the center of the perfused area to sample coronary
venous blood. The drained venous blood was collected in a
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reservoir placed at the level of the left atrium and was returned
via the jugular vein. Left ventricular pressure was measured
using a micromanometer (Konigsberg P-5, Pasadena, Califor-
nia) placed through the apex into the left ventricular cavity.
Two paired ultrasonic crystals were placed in the inner one-
third of the myocardium approximately one centimeter apart
to measure the myocardial segment length with an ultrasonic
dimension gauge (Schuessler, 5MHz). End-diastolic length was
determined at the R wave of the electrocardiogram, and
end-systolic length was determined at the minimal dP/dt (14).
Fractional shortening (FS) was calculated by ([end-diastolic
length]-[end-systolic length])/(end-diastolic length) and served
as an index for myocardial contractility of the perfused area.
At the end of Protocols I–III, Evans blue was infused into
the coronary artery via the bypass tube to identify the perfused
area. We cut and weighed the perfused myocardium to nor-
malize CBF.
Experimental Protocols
Protocol I: Effects of an intracoronary administration of
benidipine on coronary hemodynamic and metabolic parame-
ters in the non-ischemic myocardium. Five dogs were used in
this protocol. Coronary arterial and venous blood were sam-
pled for blood gas analysis and determination of adenosine and
end products of NO (nitrate 1 nitrite) concentrations. Hemo-
dynamic functions, that is, left ventricular pressure, dP/dt, and
segment length of the perfused area, were measured. Four
doses (25, 50, 100, and 200 ng/kg/min) of benidipine were
randomly administered into the LAD for 5 min (n 5 5) each.
It took 3 min to obtain stable coronary hemodynamic condi-
tions. Between 4 and 5 min during each infusion of benidipine,
coronary arterial and venous blood were sampled and systemic
and coronary hemodynamic parameters were measured. In the
same dogs, we infused benidipine with the same four doses
each for 5 min under the treatment with either Lv-nitro
arginine methyl ester (L-NAME, 10 mg/kg/min) or
8-sulfophenyltheophylline (8-SPT, 50 mg/kg/min). In a prelim-
inary study, we confirmed that the dose of L-NAME attenuates
the coronary vasodilatory action of bradykinin (20 ng/kg/min,
ic) by 85 6 6%, and 8-SPT attenuates the coronary vasodila-
tory action of adenosine (4 mg/kg/min) by 82 6 5%, respec-
tively. Either L-NAME or 8-SPT was administered into the
LAD 5 min before the administration of benidipine. We
measured the hemodynamic parameters and sampled the
coronary arterial and venous blood four minutes after the
onset of infusion of either L-NAME or 8-SPT.
Protocol II: Effects of benidipine on coronary hemodynamic
and metabolic parameters in the ischemic myocardium (con-
stant low CPP). Twenty-two dogs were used in this protocol.
After hemodynamic stabilization, CPP was reduced so that
CBF was decreased to 33% of the control CBF, using an
occluder attached at the extracorporeal bypass tube. After a
low level of CPP was obtained, the occluder was adjusted to
keep CPP constant. All of the hemodynamic parameters were
measured 10 min after the onset of hypoperfusion, and both
coronary arterial and venous blood were sampled. In five dogs,
Table 1. Systemic Hemodynamic Parameters in Protocols I–III
Systolic BP Mean BP Heart Rate
Protocol I
Before administration
No pretreatment 135 6 6 105 6 4 145 6 7
L-NAME 142 6 5 110 6 8 139 6 6
8-SPT 139 6 5 107 6 7 144 6 8
After administration
N pretreatment — — —
L-NAME 137 6 6 105 6 7 139 6 7
8-SPT 143 6 6 103 6 5 143 6 5
Protocol II
Before ischemia
No pretreatment 141 6 5 103 6 6 142 6 7
L-NAME 140 6 4 108 6 5 143 6 5
8-SPT 145 6 6 106 6 4 137 6 7
During ischemia without benidipine
No pretreatment 142 6 5 102 6 5 139 6 6
L-NAME 138 6 6 111 6 6 140 6 6
8-SPT 143 6 4 103 6 4 141 6 7
During ischemia with benidipine
No pretreatment 144 6 5 105 6 5 145 6 5
L-NAME 143 6 6 109 6 4 143 6 5
8-SPT 140 6 7 107 6 6 138 6 6
Protocol III
Before ischemia
No pretreatment 145 6 5 105 6 5 143 6 4
L-NAME 138 6 4 102 6 4 144 6 5
During ischemia without benidipine
No pretreatment 144 6 6 106 6 4 139 6 5
L-NAME 141 6 5 101 6 5 143 6 5
During ischemia with benidipine
No pretreatment 138 6 7 104 6 5 138 6 5
L-NAME 138 6 6 100 6 4 135 6 7
Values are mean 6 SEM. Abbreviations: L-NAME 5 Lv-nitro arginine
methyl ester; 8-SPT 5 8-sulfophenyltheophylline. There is no significant differ-
ences in each parameter between each group or between each condition.
Abbreviations and Acronyms
Ca 5 calcium
CBF 5 coronary blood flow
CPP 5 coronary perfusion pressure
FS 5 fractional shortening
GMP 5 guanosine monophosphate




5 levels of nitrate 1 nitrite or adenosine
in the coronary venous blood over the
arterial blood, respectively
L-NAME 5 Lv-nitro arginine methyl ester
NO 5 nitric oxide
8-SPT 5 8-sulfophenyltheophylline
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we tested the stability of the severity of ischemia for another
20 min, because previous studies indicate that myocardial
ischemia may be changed during coronary hypoperfusion
(15,16). In other dogs, benidipine (100 ng/kg/min, n 5 7) was
infused into the LAD, and measurements of all hemodynamic
and metabolic parameters were repeated in 10 min. Thereaf-
ter, the infusion of either benidipine or the solvent was
discontinued, and hemodynamic and metabolic parameters
were observed until stabilization. In the other dogs, we infused
benidipine under the treatment with either L-NAME
(10 mg/kg/min, n 5 5) or 8-SPT (50 mg/kg/min, n 5 5) in the
ischemic myocardium. Time and order of the administrations
of the drugs before the onset of coronary hypoperfusion was
the same as in Protocol I.
Protocol III: Effects of benidipine on coronary hemody-
namic and metabolic parameters in the ischemic myocardium
(constant low CBF). Because increased CBF may increase
share stress of coronary artery, which may secondarily increase
cardiac NO levels in the ischemic hearts, we tested the effects
of benidipine on cardiac NO levels in the constant low CPP
condition. In 10 dogs, after hemodynamic stabilization, CPP
was reduced so that CBF was decreased to 33% of the control
CBF, using an occluder attached at the extracorporeal bypass
tube. After a low level of CPP and CBF was obtained, the
occluder was adjusted to keep CBF constant. All of the
hemodynamic parameters were measured 10 min after the
onset of hypoperfusion, and both coronary arterial and venous
blood were sampled. After these measurements, benidipine
(100 ng/kg/min, n 5 5) was infused into the LAD, and
measurements of all hemodynamic and metabolic parameters
were repeated in 10 min. Thereafter, the infusion of benidipine
was discontinued, and hemodynamic and metabolic parame-
ters were observed until stabilization. In the other dogs, we
infused benidipine under the treatment with L-NAME
(10 mg/kg/min, n 5 5) in the ischemic myocardium. Time and
order of the administrations of the drugs before the onset of
coronary hypoperfusion was the same as in Protocol II.
Protocol IV: Effects of benidipine on cyclic guanosine
monophosphate (GMP) content of epicardial coronary arter-
ies in ischemic hearts. In 20 dogs, we investigated whether
benidipine increases the cyclic guanosine monophosphate
(GMP) content of the epicardial arteries in the ischemic
myocardium. With an occluder attached at the extracorporeal
bypass tube, coronary perfusion pressure was reduced so that
CBF decreased to one-third of the control coronary blood
flow. After a low CPP was established, the occluder was
Figure 1. The changes in CBF during intracoronary administration of
benidipine with and without L-NAME or 8-SPT. Statistical analysis
was performed by ANOVA followed by Bonferoni’s test.
Figure 2. Changes in NOx (nitrate 1 nitrite) levels in the coronary
venous blood over the arterial blood during intracoronary administra-
tions of benidipine in the ischemic myocardium (the CPP 5 constant
model). Benidipine increased cardiac NO levels, which were blunted
by L-NAME. Statistical analysis was performed by ANOVA followed
by Bonferoni’s test.
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adjusted to keep CPP at a constant low level. After this low
CPP was maintained for 10 min, we infused either benidipine
(100 ng/kg/min, n 5 10) or the solvent (polyethylene glycol 400,
0.0167 ml/kg/min, n 5 10) into the left anterior descending
coronary artery for 10 min with and without L-NAME. Next,
we rapidly removed the epicardial left anterior descending
(ischemic region) and left circumflex (nonischemic control
region) coronary arteries with precooled scissors and a tongue
and stored them in liquid nitrogen.
Chemical Analysis. Lactate concentration was assessed by
the enzymatic assay (17). Lactate extraction ratio (LER) was
obtained by multiplying the coronary arteriovenous differences
in the lactate concentrations by 100 and dividing it by the
arterial lactate concentration (18).
The methods of the measurements of plasma NO (19,20),
and adenosine levels (21) have been reported previously. The
method of the measurements of cyclic GMP levels in tissues
have been previously described (22,23).
Statistical Analysis. Statistical analysis was performed
among the groups and in the time courses of the hemodynamic
and metabolic parameters using analysis of variance (24,25).
When analysis of variance revealed significant differences,
Bonferroni probabilities were examined (25). All values were
expressed as mean 6 SEM. The p value of ,0.05 was
considered significant.
Results
Effects of benidipine on the coronary hemodynamic and
metabolic functions in the nonischemic myocardium. Either
L-NAME or 8-SPT did not change either systolic and diastolic
blood pressure, heart rate or CPP in the nonischemic condition
(Table 1). In the untreated condition, benidipine increased the
levels of nitrate 1 nitrite in the coronary venous blood over the
arterial blood (DVA(NO)) (3.9 6 0.7 nmol/ml at control, 4.9 6
0.6 (p , 0.05 vs. the control), 5.8 6 0.6 (p , 0.05), 7.2 6 0.6
(p , 0.05), and 7.1 6 0.3 nmol/ml (p , 0.05) during an
intracoronary infusion of benidipine of 25, 50, 100, and 200
ng/kg/min, respectively); however, it did not affect the levels of
adenosine in the coronary venous blood over the arterial blood
(DVA(Ado)) (5.5 6 1.3 pmol/ml at control, 4.6 6 1.0, 5.1 6
0.6, 5.3 6 0.6, and 4.7 6 1.2 pmol/ml (p , 0.05) during an
Figure 3. Changes in CPP (left panel) and
CBF (right panel) during the infusion and
withdrawal of benidipine during coronary
hypoperfusion. Although the reduced CPP
was maintained at a constant level, beni-
dipine increased CBF, which was blunted
by L-NAME. Statistical analysis was per-
formed by ANOVA followed by Bonfero-
ni’s test.
Figure 4. Changes in fractional shorten-
ing (left panel) and lactate extraction
ratio (right panel) during the infusion
and withdrawal of benidipine during cor-
onary hypoperfusion (CPP 5 constant at
the low level). Statistical analysis was
performed by ANOVA followed by Bon-
feroni’s test.
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intracoronary infusion of four doses of benidipine, respective-
ly). Benidipine increased CBF dose-dependency (Fig. 1), which
was partially attenuated by L-NAME, but not by 8-SPT.
Effects of intracoronary administration of benidipine on
the coronary hemodynamic and metabolic functions in the
ischemic myocardium. Either heart rate, systolic and diastolic
blood pressure were unchanged with and without pharmaco-
logical interventions (Table 1). Without benidipine infusion,
after the reduction of CPP (104 6 4 mmHg at control; 41 6 2,
41 6 2, 41 6 2, and 41 6 2 mmHg at 5, 10, 20, and 30 min after
the onset of coronary hypoperfusion, respectively), CBF (93 6
3 ml/100g/min at control; 31 6 2, 32 6 3, 30 6 3, and 30 6 4
ml/100g/min at 5, 10, 20, and 30 min, respectively), FS (26.7 6
3.1 mmHg at control; 4.9 6 1.2, 4.8 6 1.5, 5.2 6 1.4, and 4.6 6
1.5% at 5, 10, 20, and 30 min, respectively) and LER (27.8 6
3.9% at control, 253.2 6 4.9, 246.7 6 7.8, 252.7 6 4.5, and
262.3 6 6.5% at 5, 10, 20, and 30 min after the onset of
coronary hypoperfusion, respectively) did not change signifi-
cantly for 30 min of coronary hypoperfusion.
Ten minutes after the reduction in CPP, DVA(NO) in-
creased (Fig. 2), and benidipine further increased DVA(NO).
In accordance with the increases in DVA(NO), benidipine
increased CBF despite the constant CPP (Fig. 3). Fractional
shortening and LER, which was reduced after the onset of
coronary hypoperfusion, increased due to benidipine adminis-
tration (Fig. 4). These beneficial effects of benidipine on the
ischemic heart were attenuated by L-NAME but not by 8-SPT.
In the ischemic hearts with the low constant CBF condition,
benidipine increased DVA(NO) and was attenuated by
L-NAME (Fig. 5). Benidipine decreased CPP because of the
coronary vasodilatory capability, which was prevented by
L-NAME (Fig. 6). Since CBF remained constant, neither FS
nor LER was altered (Fig. 7).
We measured cyclic GMP levels in the epicardial coronary
artery; without L-NAME (CPP: 103 6 3 to 43 6 2 mmHg,
CBF: 91 6 2 to 31 6 2 ml/100g/min), benidipine increased the
cyclic GMP levels of the epicardial coronary arteries and this
effect was blunted by L-NAME (Fig. 8).
Discussion
This is the first report that a dihydropyridine Ca channel
blocker, benidipine, has the capability of increasing cardiac
NO levels in ischemic hearts, which mediates coronary vaso-
dilation and attenuates the severity of myocardial ischemia.
Figure 5. Changes in NOx (nitrate 1 nitrite) levels in the coronary
venous blood over the arterial blood during intracoronary administra-
tions of benidipine in the ischemic myocardium (the CBF 5 constant
model). Benidipine increased cardiac NO levels, which were blunted
by L-NAME. Statistical analysis was performed by ANOVA followed
by Bonferoni’s test.
Figure 6. Changes in CBF (left panel)
and CPP (right panel) during the infusion
and withdrawal of benidipine during cor-
onary hypoperfusion. Although the re-
duced CBF was maintained at a constant
level, benidipine decreased CPP, which
was blunted by L-NAME. Statistical anal-
ysis was performed by ANOVA followed
by Bonferoni’s test.
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Since it is reported that amlodipine also increases NO levels in
canine coronary microvessels (26), the capability of enhancing
the effects of NO may not be attributable to the specific nature
of benidipine, but the general characteristics of a dihydropyr-
idine Ca channel antagonist, although the potency of the
capability to enhance the NO levels due to Ca channel
antagonists may be different.
Benidipine-induced coronary vasodilation in nonischemic
and ischemic hearts. Because Ca channel blockers can inhibit
adenosine uptake into the cells (12,13) and adenosine is a very
potent coronary vasodilator (27), we at first thought that
adenosine-mediated mechanisms may be involved in
benidipine-induced coronary vasodilation, although they were
not. On the contrary, benidipine increased the cardiac NO
levels and benidipine-induced coronary vasodilation was
blunted by L-NAME, indicating that NO-dependent mecha-
nisms may be involved in benidipine-induced coronary vasodi-
lation. However, it is quite different with regard to the extent
of the involvement of NO in benidipine-induced coronary
vasodilation between the ischemic and nonischemic hearts
(Fig. 1 and 3). There are three possibilities that explain this
difference. First of all, if the open probability of Ca channels in
coronary smooth muscles is high in the nonischemic heart
compared with the ischemic hearts, the capability for Ca
channel blockers to inhibit Ca channels may be high enough to
blunt the NO-dependent coronary vasodilation due to benidip-
ine in the nonischemic hearts. On the other hand, if myocardial
ischemia already decreases the open probability of Ca chan-
nels, only a slight potency may be left for benidipine to cause
further coronary vasodilation via antagonization of Ca chan-
nels, and the relative importance of NO-dependent coronary
vasodilation may increase. Indeed, endothelial-dependent hy-
perpolarization factor is released in the ischemic myocardium
(28,29), which may hyperpolarize the cellular membrane, and
it may decrease the open probability of Ca channels of
coronary smooth muscles in the ischemic hearts. Secondly,
since ischemia per se activates NO synthase via endogenous
neurohumoral substances such as catecholamine, bradykinin
and adenosine in the ischemic hearts, benidipine can further
increase the activity of NO synthase that has been partially
activated. Considering that the dose and action curves are
generally sigmoidal, the extent of the increases in NO synthase
may be augmented in the ischemic hearts compared with
Figure 8. Cyclic GMP levels in the epicardial coronary artery in the
nonischemic (control, LCX) and ischemic (LAD) areas with and
without benidipine in the presence or absence of L-NAME. Statistical
analysis was performed by ANOVA followed by Bonferoni’s test.
Figure 7. Changes in fractional shortening
(left panel) and lactate extraction ratio
(right panel) during the infusion and with-
drawal of benidipine during coronary hypo-
perfusion (CBF 5 constant at the low level).
Statistical analysis was performed by
ANOVA followed by Bonferoni’s test.
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nonischemic hearts during infusions of benidipine. Third, the
capability to increase the cardiac NO levels due to benidipine
may be higher in ionic and neurohumoral circumstances of
ischemic hearts than in nonischemic hearts. We did not
determine which factor is likely to explain the difference.
The mechanisms of benidipine-induced increases in NO
levels in ischemic hearts. Since Ca channel blockers increase
CBF via inhibition of Ca21 entry into smooth muscle cells (3)
and increases in shear stress in the endothelial cells due to
increases in CBF increase NO production, one may argue that
increases in NO levels due to benidipine are secondary to the
increases in shear stress during the increases in CBF. However,
in the present study, even when CBF was kept constant at a low
level during infusion of benidipine, the cardiac NO levels were
increased. This result indicates that benidipine directly affects
the metabolism of NO. There are several stimuli to facilitate
the NO production. Most of all, benidipine is reported to
activate kallikrein in the kidney (30), which may increase
bradykinin production in the heart. Indeed, it is reported that
NO-dependent vasodilation due to amlodipine is partially
attributable to bradykinin (26).
Limitation, and pathophysiological and clinical relevance.
Although we used anesthetized open chest dogs, there are
substantial differences between the anesthetized and conscious
animals (31–33). In the conscious dogs, inhibition of nitric
oxide synthase distal to a coronary stenosis reduced myocardial
perfusion (31,32). In contrast, CPP in the L-NAME group
during ischemia (45.8 6 3.9 mm Hg) were slightly higher than
the control group (42.5 6 1.4 mm Hg), but there was no
significant difference (p 5 0.299). This result suggests that the
NO-generating system may be weak in our model compared
with the conscious dog models. However, this may be attrib-
utable to the variation in the physiological condition of the
dogs. When L-NAME was administered into the coronary
artery 10 min after the onset of coronary hypoperfusion in each
dog, we found that coronary blood was decreased by about
30% in the anesthetized animals (18), suggesting that NO still
works in the regulation of coronary vascular tones in the
ischemic hearts. Furthermore, there is a difference in re-
cruitable coronary flow reserve during ischemia in anesthetized
and conscious animals (33); conscious dogs may have less
recruitable flow reserve during ischemia compared with anes-
thetized animals. Since coronary vascular tone in the anesthe-
tized animals may be higher compared with that of the
conscious animals, we need to be careful to extend the present
results to the clinical settings.
In turn, nitric oxide is believed to attenuate the severity of
myocardial ischemia; NO increases CBF, attenuates the myo-
cardial anaerobic metabolism, inhibits platelet aggregation and
leukocytes activation, and attenuates the activation of sympa-
thetic activity in ischemic hearts. Since the present study
revealed that NO-dependent mechanisms are involved in the
effects of benidipine, benidipine may be beneficial for ischemic
hearts compared with other Ca channel antagonists. Further-
more, NO is reported to mediate cardioprotection at a late
phase of ischemic preconditioning: 24 or 48 h after a brief
period of ischemia mediates the infarct size-limiting effects
(34,35) or the attenuation of myocardial stunning (36), and
these are blunted by L-NAME.
Taken together, benidipine, a dihydropyridine Ca chan-
nel blocker, can be considered as an agent to mediate or
enhance the NO-dependent cardioprotection in the dis-
eased heart.
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